WhatsApp Skip to main content

Dr. Harsh J Shah

A new treatment, CT041, is bringing hope to patients with advanced pancreatic cancer. This therapy uses modified T-cells to target cancer cells and has shown encouraging results. In a recent study, patients who received CT041 had a median overall survival of 10 months.
Despite some side effects like blood-related issues and digestive problems, the therapy was generally well-tolerated. Out of 24 patients, 70.8% saw their disease controlled, and many experienced a significant reduction in cancer markers.
While these results are promising, more research is needed to fully understand the benefits. If you or a loved one has advanced pancreatic cancer, discuss new treatment options with your doctor.
Read the full article here

Rate this post

Leave a Reply

Your email address will not be published. Required fields are marked *

Dr. Harsh J Shah
Dr Harsh Shah - GI & HPB Oncosurgeon in India
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.